AstraZeneca finances R&D Postdoctoral Challenge finalists
Six finalists awarded completely funded postdoctoral exploration positions
AstraZeneca has agreed to fund all six finalists from the R&D Postdoctoral Challenge with exploration positions for two times at one of the Company’s strategic R&D centres in Cambridge, UK, Gaithersburg, US or Gothenburg, Sweden.
Unlike traditionalpre-defined assiduity postdoctoral enterprise, the Challenge which launched in March 2022, encouraged early career scientists to submit their own exploration proffers to accelerate medicine discovery for some of the world’s most complex conditions.
From further than 120 proffers, six winners were named by a judging panel of AstraZeneca and external life wisdom leaders, grounded on scientific merit and eventuality to produce a real impact for cases, society and healthcare systems.
Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said “ We launched the R&D Postdoctoral Challenge to promote diversity of study and stimulate exploration openings across the globe. The final event was successful in bringing together the brightest minds to help them turn their ideas into meaningful benefits for cases and energy their early career development. I look forward tore-running the programme in unborn times. ”
The winners from Africa, the Middle East and Europe have been awarded completely funded postdoctoral exploration positions with access to the Company’s moxie, composites, new tools and technologies, and mentoring support to turn their ideas into reality.
The R&D Postdoctoral Challenge forms part of AstraZeneca’s commitment to supporting early gift, furnishing openings to work within a different and inclusive terrain that enables wisdom to thrive.
AstraZeneca’s global R&D footmark and productivity
In 2021 AstraZeneca invested$ 8 billion in R&D, around 21 of the Company’s development, in order to continue to discover and develop drugs which transfigure the lives of cases.
The Company has three world class strategic R&D centres including The Discovery Centre( Slice) in Cambridge in the UK, one in Gaithersburg, Maryland in the lesser Washington,D.C. region of the US, and another in Gothenburg in Sweden, as well as farther capitals across the world. It has integrated R&D brigades and accelerated decision- making processes, using its unique scientific capabilities, to deliver one of the most productive channels in the assiduity.
Since 2005, AstraZeneca has achieved an nearlysix-fold enhancement in the proportion of its channel motes that have advanced from preclinical disquisition to completion of Phase III clinical trials – from 4 to 23. This enhancement moves AstraZeneca well above the current assiduity average success rate of 14 in the 2018- 2020 timeframe.1
Of the Company’s,000 workers, further than,000 work simply in R&D. In 2021, its scientists published a aggregate of 871 calligraphies, with 196 in high impact peer- review journals( impact factor lesser than or equal to 15 according to Reuters five- time standing), compared to one in 2010.
AstraZeneca( LSE/ STO/ Nasdaq AZN) is a global, wisdom- led biopharmaceutical company that focuses on the discovery, development, and commercialisation of tradition drugs in Oncology, Rare conditions, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Grounded in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative drugs are used by millions of cases worldwide.